Last A$0.02 AUD
Change Today +0.001 / 6.25%
Volume 212.3K
PAB On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 10:10 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

patrys ltd (PAB) Snapshot

Open
A$0.02
Previous Close
A$0.02
Day High
A$0.02
Day Low
A$0.02
52 Week High
01/2/14 - A$0.06
52 Week Low
12/8/14 - A$0.01
Market Cap
11.9M
Average Volume 10 Days
435.3K
EPS TTM
A$-0.01
Shares Outstanding
697.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PATRYS LTD (PAB)

Related News

No related news articles were found.

patrys ltd (PAB) Related Businessweek News

No Related Businessweek News Found

patrys ltd (PAB) Details

Patrys Limited develops natural human antibody therapeutics for the treatment of cancer in Australia. The company’s clinical products include PAT-SM6, a natural human antibody used for the treatment of multiple types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers that include multiple myeloma; and PAT-SC1 for treating gastric cancer and solid tumors. It also has late stage preclinical products, such as PAT-LM1, a natural human antibody that is used in the treatment for multiple types of cancer against colon, lung, breast, ovary, and pancreatic cancers. The company was founded in 2006 and is headquartered in Melbourne, Australia.

10 Employees
Last Reported Date: 09/9/14
Founded in 2006

patrys ltd (PAB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$259.5K
Vice President of Research & Development and ...
Total Annual Compensation: A$217.8K
Senior Director of Business Development
Total Annual Compensation: A$124.8K
Compensation as of Fiscal Year 2014.

patrys ltd (PAB) Key Developments

Patrys Limited Appoints James Campbell as Non-Executive Director, Effective November 12, 2014

Patrys Limited announced the appointment, effective from the close of 2014 AGM on November 12, 2014, of Dr. James Campbell as a Non-Executive Director. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited with responsibilities ranging from IP management through to licensing and business development. More recently Dr. Campbell has guided the creation, through acquisition, of Invion Limited as an executive director and remains a non-executive director of that company, and has assisted private biotechnology companies in New Zealand and the USA with capital raising and partnering negotiations. Dr. Campbell is also a Non-Executive Director of BioProspect Limited.

Patrys Limited, Annual General Meeting, Nov 12, 2014

Patrys Limited, Annual General Meeting, Nov 12, 2014.

Patrys Limited Announces Management Changes

Patrys Limited provided an update on the status of its transition planning following the resignation of Dr. Marie Roskrow as Managing Director and CEO last month. In order to facilitate a smooth transition to the existing management team it has been determined that Dr. Roskrow will retire from the Company with immediate effect. Mr. Roger McPherson, CFO and Company Secretary, has been appointed as interim CEO pending the appointment of a permanent replacement CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PAB:AU A$0.02 AUD +0.001

PAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PAB.
View Industry Companies
 

Industry Analysis

PAB

Industry Average

Valuation PAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.0x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PATRYS LTD, please visit www.patrys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.